FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039432873> ?p ?o ?g. }

• W3039432873 endingPage "142" @default.
• W3039432873 startingPage "137" @default.
• W3039432873 abstract "IntroductionIn the phase II ATLANTIC study, durvalumab provided durable responses with acceptable tolerability in heavily pretreated patients with advanced NSCLC, across three independent patient cohorts defined by EGFR/ALK status and tumour PD-L1 expression. Preliminary overall survival (OS) data were encouraging. We now report final OS and updated safety data.MethodsPatients with advanced NSCLC with disease progression following ≥2 previous systemic regimens received durvalumab 10 mg/kg every 2 weeks. The primary endpoint was objective response rate among patients with increased PD-L1 expression (defined as ≥25 % or ≥90 % of tumour cells [TCs], cohort-dependent). Secondary endpoints included OS and safety.Results444 patients received durvalumab: 111 in Cohort 1 (EGFR+/ALK+), 265 in Cohort 2 (EGFR−/ALK−), and 68 in Cohort 3 (EGFR−/ALK−; TC ≥ 90 %). Median (95 % CI) OS was 13.3 months (6.3–24.5) in patients with EGFR+/ALK+ NSCLC with TC ≥ 25 %, 10.9 months (8.6–13.6) in patients with EGFR–/ALK– NSCLC with TC ≥ 25 %, and 13.2 months (5.9–not reached) in patients with EGFR–/ALK– NSCLC with TC ≥ 90 %. Median (95 % CI) OS was slightly shorter in patients with TC < 25 % (9.9 months [4.2–13.3] in patients with EGFR+/ALK+ NSCLC and 9.3 months [5.9–10.8] in those with EGFR–/ALK– NSCLC). Treatment-related adverse events of special interest occurred with similar incidences as reported previously.ConclusionsAfter additional follow-up, final OS data remain encouraging across all cohorts, further supporting the clinical activity of durvalumab in patients with heavily pretreated advanced NSCLC, including those with EGFR+/ALK+ tumours. There were no new safety signals." @default.
• W3039432873 created "2020-07-10" @default.
• W3039432873 creator A5000488526 @default.
• W3039432873 creator A5005188570 @default.
• W3039432873 creator A5007121755 @default.
• W3039432873 creator A5016370905 @default.
• W3039432873 creator A5021704329 @default.
• W3039432873 creator A5022984824 @default.
• W3039432873 creator A5030107272 @default.
• W3039432873 creator A5032293215 @default.
• W3039432873 creator A5032617538 @default.
• W3039432873 creator A5040900859 @default.
• W3039432873 creator A5052379271 @default.
• W3039432873 creator A5055246540 @default.
• W3039432873 creator A5064697305 @default.
• W3039432873 creator A5072483780 @default.
• W3039432873 creator A5075877134 @default.
• W3039432873 creator A5089891961 @default.
• W3039432873 creator A5090977453 @default.
• W3039432873 creator A5091509029 @default.
• W3039432873 date "2020-09-01" @default.
• W3039432873 modified "2023-10-16" @default.
• W3039432873 title "Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study" @default.
• W3039432873 cites W2106511606 @default.
• W3039432873 cites W2198093519 @default.
• W3039432873 cites W2293531514 @default.
• W3039432873 cites W2293828571 @default.
• W3039432873 cites W2400514548 @default.
• W3039432873 cites W2509195076 @default.
• W3039432873 cites W2567564314 @default.
• W3039432873 cites W2625684877 @default.
• W3039432873 cites W2626831245 @default.
• W3039432873 cites W2769570103 @default.
• W3039432873 cites W2784012638 @default.
• W3039432873 cites W2791290180 @default.
• W3039432873 cites W2791803000 @default.
• W3039432873 cites W2924289105 @default.
• W3039432873 doi "https://doi.org/10.1016/j.lungcan.2020.06.032" @default.
• W3039432873 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32702570" @default.
• W3039432873 hasPublicationYear "2020" @default.
• W3039432873 type Work @default.
• W3039432873 sameAs 3039432873 @default.
• W3039432873 citedByCount "31" @default.
• W3039432873 countsByYear W30394328732021 @default.
• W3039432873 countsByYear W30394328732022 @default.
• W3039432873 countsByYear W30394328732023 @default.
• W3039432873 crossrefType "journal-article" @default.
• W3039432873 hasAuthorship W3039432873A5000488526 @default.
• W3039432873 hasAuthorship W3039432873A5005188570 @default.
• W3039432873 hasAuthorship W3039432873A5007121755 @default.
• W3039432873 hasAuthorship W3039432873A5016370905 @default.
• W3039432873 hasAuthorship W3039432873A5021704329 @default.
• W3039432873 hasAuthorship W3039432873A5022984824 @default.
• W3039432873 hasAuthorship W3039432873A5030107272 @default.
• W3039432873 hasAuthorship W3039432873A5032293215 @default.
• W3039432873 hasAuthorship W3039432873A5032617538 @default.
• W3039432873 hasAuthorship W3039432873A5040900859 @default.
• W3039432873 hasAuthorship W3039432873A5052379271 @default.
• W3039432873 hasAuthorship W3039432873A5055246540 @default.
• W3039432873 hasAuthorship W3039432873A5064697305 @default.
• W3039432873 hasAuthorship W3039432873A5072483780 @default.
• W3039432873 hasAuthorship W3039432873A5075877134 @default.
• W3039432873 hasAuthorship W3039432873A5089891961 @default.
• W3039432873 hasAuthorship W3039432873A5090977453 @default.
• W3039432873 hasAuthorship W3039432873A5091509029 @default.
• W3039432873 hasBestOaLocation W30394328731 @default.
• W3039432873 hasConcept C121608353 @default.
• W3039432873 hasConcept C126322002 @default.
• W3039432873 hasConcept C143998085 @default.
• W3039432873 hasConcept C197934379 @default.
• W3039432873 hasConcept C203092338 @default.
• W3039432873 hasConcept C2777701055 @default.
• W3039432873 hasConcept C2777742743 @default.
• W3039432873 hasConcept C2778375690 @default.
• W3039432873 hasConcept C2780030458 @default.
• W3039432873 hasConcept C535046627 @default.
• W3039432873 hasConcept C71924100 @default.
• W3039432873 hasConcept C72563966 @default.
• W3039432873 hasConceptScore W3039432873C121608353 @default.
• W3039432873 hasConceptScore W3039432873C126322002 @default.
• W3039432873 hasConceptScore W3039432873C143998085 @default.
• W3039432873 hasConceptScore W3039432873C197934379 @default.
• W3039432873 hasConceptScore W3039432873C203092338 @default.
• W3039432873 hasConceptScore W3039432873C2777701055 @default.
• W3039432873 hasConceptScore W3039432873C2777742743 @default.
• W3039432873 hasConceptScore W3039432873C2778375690 @default.
• W3039432873 hasConceptScore W3039432873C2780030458 @default.
• W3039432873 hasConceptScore W3039432873C535046627 @default.
• W3039432873 hasConceptScore W3039432873C71924100 @default.
• W3039432873 hasConceptScore W3039432873C72563966 @default.
• W3039432873 hasFunder F4320307770 @default.
• W3039432873 hasLocation W30394328731 @default.
• W3039432873 hasLocation W30394328732 @default.
• W3039432873 hasOpenAccess W3039432873 @default.
• W3039432873 hasPrimaryLocation W30394328731 @default.
• W3039432873 hasRelatedWork W1556562895 @default.
• W3039432873 hasRelatedWork W2053485995 @default.
• W3039432873 hasRelatedWork W2745465965 @default.

• next